Skip to main content
Home > SciBX > Tools

Chronological Index of : Tools

 Current Issue
  • Toxic assets

    A tool for in vivo detection of liver toxicity could represent a substantial improvement over in vitro methods. The litmus test for the Stanford University inventors will be to show that the nanoparticle-based method …

    Published on 4/10/2014
  • Figure 1: Bird's-eye view of IgG hexamers

    Tools: Complementing mAbs Figure 1. Bird's-eye view of IgG hexamers. The complement component 1 q subcomponent (C1q) complex has six antibody-binding headpieces (blue circles) and activates the complement system. …

    Published on 4/3/2014
  • Complementing mAbs

    Genmab and Utrecht University researchers have shown that hexameric IgG complexes can activate the complement cascade. Genmab is now selecting key mutations and antibody candidates to generate IgG antibodies that …

    Published on 4/3/2014
  • Plasma lipids: harbingers of AD?

    A team of U.S. researchers has shown that a panel of plasma lipid markers could predict Alzheimer's disease. The panel could enrich clinical trials testing disease-modifying therapies, but validation studies must first …

    Published on 3/20/2014
  • Hitchhiker's guide to the lymph node

    An MIT team has provided a recipe for delivering cancer vaccines to lymph nodes by tethering them to albumin. In proof-of-concept studies in mice, lymph node-targeted tumor antigens and adjuvants elicited strong immune …

    Published on 3/13/2014
  • Taking TIMP3 to heart

    A U.S. team has leveraged the cardioprotective activity of TIMP3 using a formulation and delivery strategy that avoids off-target effects. Preclinical data indicate that the procedure could help prevent heart failure …

    Published on 3/6/2014
  • (Pluri)potent acid

    Researchers have generated pluripotent mouse stem cells by simply exposing somatic cells to low pH. If other researchers can replicate it - something they have thus far failed to do - the minimally invasive technique …

    Published on 2/27/2014
  • Figure 1: Ubiquibodies

    Tools: Degradation from within Figure 1. Ubiquibodies. Portnoff et al. have demonstrated a strategy for targeted destruction of intracellular proteins using engineered intracellular antibodies that deliver ubiquitin …

    Published on 2/20/2014
  • Degradation from within

    A Cornell group has proof of concept for proteasomal degradation of intracellular proteins using designer binding proteins to deliver ubiquitin to their targets. The challenge for Ubiquizyme, a newco formed around this …

    Published on 2/20/2014
  • Micromanaging the microenvironment

    A Massachusetts team has designed an in vivo shRNA screen to discover tumor targets that can improve the efficacy of T cell immunotherapies. The system showed that current checkpoint inhibitors barely scratch the …

    Published on 2/13/2014
  • Figure 1: In vivo shRNA discovery of immunotherapy targets

    Tools: Micromanaging the microenvironment Figure 1. In vivo shRNA discovery of immunotherapy targets. T cells infected with shRNA libraries were injected into mice with melanoma. Several days later, T cells were …

    Published on 2/13/2014
  • RNA is for activation

    Although siRNAs have been validated as therapeutics to knock down gene expression, short double-stranded RNAs can also turn on gene expression. An academic team sponsored by MiNA Therapeutics has attacked liver cancer …

    Published on 2/6/2014
  • Diagnosing narcolepsy

    A new way to diagnose narcolepsy using T cells could help Jazz Pharmaceuticals find patients eligible to take Xyrem. In addition, GlaxoSmithKline wants to use the findings to develop influenza vaccines that lack the …

    Published on 1/23/2014
  • Silencing KRAS

    Oncogenic KRAS is notoriously difficult to target. Silenseed thinks its localized, sustained siRNA delivery technology, dubbed LODER, provides a viable strategy and also addresses issues of tissue targeting, cellular …

    Published on 1/9/2014
  • Family seeds

    In attempting to make specific microRNA inhibitors, companies have assumed that anti-miRNAs should approximate the length of the miRNA target. Now, an international team has generated in vivo proof of concept that …

    Published on 12/12/2013
  • Plan B for anti-miRNA

    How to formulate and deliver therapeutic anti-microRNAs has been a big challenge in the burgeoning anti-miRNA space. Now, a San Diego team has proof of concept for a surprisingly simple way to deliver these molecules …

    Published on 12/12/2013
  • Figure 1: Anti-miRNA delivery by B cells

    Tools: Plan B for anti-miRNA Figure 1. Anti-miRNA delivery by B cells. Almanza et al. have engineered B cells to deliver anti-microRNA to other immune cells. The findings suggest a new avenue for delivering …

    Published on 12/12/2013
  • Naive human iPS cells

    The inability to generate fully undifferentiated human iPS cells in vitro may contribute to inefficient and inconsistent differentiation of the cells. An Israeli team thinks a small molecule and cytokine cocktail …

    Published on 11/21/2013
  • Figure 1: Restoring dermal integrity

    Tools: Scleroderma models: skin in the game Figure 1. Restoring dermal integrity. A study from Gerber et al. has elucidated potential mechanisms by which mutations in the integrin-binding domain of fibrillin 1 (Fbn1)…

    Published on 11/14/2013
  • Scleroderma models: skin in the game

    North American researchers have mouse data showing that mutated fibrillin 1 recapitulates skin fibrosis and other symptoms seen in systemic scleroderma. The group also found downstream proteins whose expression was …

    Published on 11/14/2013
  • Phenotypic screening on target

    A Stanford-UCSF team has fished out a new class of NAMPT inhibitor using a phenotypic screen coupled with an shRNA-based target identification system. The method could have broad applicability in matching hits to …

    Published on 11/7/2013
  • Seeing CCR5

    A crystal structure of human CCR5 bound to the marketed HIV drug Selzentry reveals a unique binding site for the compound. The structural snapshot in combination with molecular modeling could guide future drug discovery…

    Published on 10/10/2013
  • Trapping human genes

    The Research Center for Molecular Medicine of the Austrian Academy of Sciences and Haplogen have generated a library of haploid knockout human cells that allows for the systematic investigation of gene function in vitro…

    Published on 9/26/2013
  • Figure 1: CAR-expressing T cell production to develop immunotherapeutics

    Tools: Supersizing adoptive T cell therapies Figure 1. CAR-expressing T cell production to develop immunotherapeutics. (I) Themeli et al. transduced a healthy volunteer's T cells with two retroviral vectors encoding …

    Published on 9/19/2013
  • Brain in a dish

    Austrian researchers grabbed headlines last month when they coaxed cultured human iPS cells into forming brain tissue, but in actuality the approach does not offer applications beyond studying very early brain …

    Published on 9/19/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993